Xerion Limited is a consumer healthcare company focused on revolutionizing standard of care in dermatology through the development and commercialization of innovative therapies and diagnostics. Xerion Limited through its wholly-owned subsidiary, Biovite Australia Pty Ltd has developed a proprietary postbiotic (AMYCOT) derived from microalgae with applications in a range of topical skincare products based on its multi-functional properties. nailKALM, the first product developed from AMYCOT, has shown clinical efficacy against onychomycosis or fungal nail infections. Our nailKALM product is sold in Australia through pharmacies, podiatrists and has just being ranged in all Chemist Warehouse stores. It is available in Singapore, Germany as well as online at Amazon.com in the USA. Additional applications of AMYCOT in other skin conditions such as acne, atopic dermatitis and psoriasis are being explored. Xerion Limited has the exclusive global commercial license to the PUFAcoatTM technology developed by Professor Robert Gibson and Dr Ge Liu of the School of Agriculture, Food and Wine, University of Adelaide. The revolutionary blood sampling product has the ability to transform certain aspects of the personalised nutrition market. The technology allows simple, accessible, personalized determination of an individual’s fatty acid profile to help improve their health and achieve their wellness goals including skin health. One application for this technology is as a companion diagnostic tool in the high value consumer supplements market for which we have a distribution agreement with BASF. BASF have recently launched PUFAcoat in the US - the largest global supplement market. PUFAcoat is a trademark owned by the University of Adelaide. Further information at www.xerion.com.au